News
06-20-2018, 07:32 AM
KIYATEC, Inc. today announced the enrollment of the first patients in a U.S. clinical study of its Ex Vivo 3D drug response assay across several difficult-to-treat solid tumors.
More... (https://www.news-medical.net/news/20180620/KIYATEC-enrolls-first-patients-with-solid-tumors-in-clinical-study-of-its-EV3D-drug-response-assay.aspx)
More... (https://www.news-medical.net/news/20180620/KIYATEC-enrolls-first-patients-with-solid-tumors-in-clinical-study-of-its-EV3D-drug-response-assay.aspx)